Strong Inflows Make Catalyst Stock an Outlier

CPRX develops and commercializes therapies for rare diseases. For instance, the company’s Firdapse product is the only evidence-based treatment for Lambert-Eaton Myasthenic syndrome and is consistently finding new patients. Also, the company thinks tariff effects will be minimal, providing no strong growth headwind.

CPRX’s first-quarter 2025 report showed a 43.6% year-over-year increase in total net revenues, to $141.4 million. Firdapse showed a 25.3% year-over-year revenue jump from strong adoption by patients. Plus, the company has more than $580 million on hand to grow and reaffirmed full-year revenue guidance of up to $565 million.

No wonder CPRX shares are up 26% this year – and they could rise more. MoneyFlows data shows how Big Money investors are once again betting heavily on the stock.

Big Money is Catalyst’s Catalyst

Institutional volumes reveal plenty. In the last year, CPRX has enjoyed strong investor demand, which we believe to be institutional support.

Each green bar signals unusually large volumes in CPRX shares. They reflect our proprietary inflow signal, pushing the stock higher:

Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with Catalyst.

Catalyst Fundamental Analysis

Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, CPRX has had strong sales and earnings growth:

• 3-year sales growth rate (+53.8%)
• 3-year EPS growth rate (+66.7%)

Source: FactSet

Also, EPS is estimated to ramp higher this year by +17.2%.

Now we know why the stock has Big Money interest. CPRX has a track record of strong financial performance.

Marrying great fundamentals with MoneyFlows software has found some big winning stocks over the long term.

Catalyst has been a top-rated stock at MoneyFlows. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases these stocks on a weekly basis.

CPRX has made the rare Outlier 20 report multiple times in the last year. The blue bars below show when CPRX was a top pick…driven by Big Money:

Tracking unusual volumes reveals the power of money flows.

This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.

Catalyst Price Prediction

The CPRX action isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no position in CPRX at the time of publication.

If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level and follow our free weekly MoneyFlows insights.